RecruitingNCT06809595

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

This recruiting study focuses on anxiety and currently lists sites or participation links in Czechia, France, Germany, Poland, United Kingdom, United States.

AnxietyOtherFrom 18 Years to 74 Years

In plain English

Key information made simple

This study exists to understand how the medication MM120 holds up over time after the earliest research stage. Researchers are trying to understand whether the medication MM120 can give earlier or clearer feedback during care. For people living with Anxiety, being understood earlier and more clearly can shape the whole care journey. If the findings are useful, they could lead to earlier recognition and more informed decisions later on. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including Preferred Research Partners, Inc in Little Rock, Psychedelic Science Institute in Los Angeles, and West Los Angeles VA Medical Center in Los Angeles. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and meeting the main study requirements, while common reasons not to take part include active substance or alcohol problems that could affect the results and other factors that could make participation unsuitable. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record

Interested?

Check my eligibility

Study reference: NCT06809595. Your email is the only field you need to provide here.

In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in Czechia.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com